Pivotal bioVenture Partners Investment Advisor
SAN FRANCISCO, CAfiles as Pivotal bioVenture Partners Investment Advisor LLC
$308m in 13 US stocks at the end of 30 June 2026. The top 10 are 95.1% of the money. It changed about 19.8% of the portfolio this quarter.
Value
$308m
Stocks
13
Top 10 share
95.1%
Turnover
19.8%
What changed this quarter
New
Bought for the first time this quarter.
- Avalyn PharmaAVLN10.3% of the fund
Added
Bought more of a stock they already held.
- VaxcytePCVX26.9% of the fund+4%
- Trevi TherapeuticsTRVI10.6% of the fund+12%
- Avalo TherapeuticsAVTX2.6% of the fund+47%
Cut
Sold some of their stake.
- Arcutis BiotherapeuticsARQT10.8% of the fund-7%
- Oculis Holding AGOCS6.8% of the fund-10%
- Zenas BioPharmaZBIO4.0% of the fund-17%
Sold out
Sold their entire stake.
Holdings
- Avalyn PharmaAVLN
- Share
- 10.3%
- Value
- $32m
- Shares
- 966,792
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| VaxcytePCVX | 26.9% | $83m | 1,425,470 | +4% |
| Arcutis BiotherapeuticsARQT | 10.8% | $33m | 1,265,283 | -7% |
| Trevi TherapeuticsTRVI | 10.6% | $33m | 1,742,672 | +12% |
| Avalyn PharmaAVLN | 10.3% | $32m | 966,792 | New |
| EvommuneEVMN | 8.3% | $26m | 1,926,943 | Held |
| MapLight TherapeuticsMPLT | 7.1% | $22m | 611,446 | Held |
| Oculis Holding AGOCS | 6.8% | $21m | 1,506,250 | -10% |
| BioAge LabsBIOA | 5.2% | $16m | 653,374 | Held |
| ImmunomeIMNM | 5.0% | $16m | 732,512 | Held |
| Zenas BioPharmaZBIO | 4.0% | $12m | 490,766 | -17% |
| Avalo TherapeuticsAVTX | 2.6% | $8m | 434,033 | +47% |
| RallybioRLYB | 1.6% | $5m | 300,579 | Held |
| Recursion PharmaceuticalsRXRX | 0.7% | $2m | 595,518 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 90.8% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.